5-MeO-pyr-T
Names
5-Methoxy-3-[2-(pyrrolidin-1-yl)ethyl]-1H-indole
Identifiers
3D model (JSmol)
YPubChem CID
CompTox Dashboard (EPA)
InChI=1S/C15H20N2O/c1-18-13-4-5-15-14(10-13)12(11-16-15)6-9-17-7-2-3-8-17/h4-5,10-11,16H,2-3,6-9H2,1H3 Y
Key: KAASYKNZNPWPQG-UHFFFAOYSA-N Y
InChI=1/C15H20N2O/c1-18-13-4-5-15-14(10-13)12(11-16-15)6-9-17-7-2-3-8-17/h4-5,10-11,16H,2-3,6-9H2,1H3
Key: KAASYKNZNPWPQG-UHFFFAOYAA
O(c3ccc1c(c(c[nH]1)CCN2CCCC2)c3)C
Properties
C15H20N2O
244.338 g·mol−1
Appearance
Off-white oil
200.3g/cm3
164 to 167 °C (327 to 333 °F; 437 to 440 K) Melting point given for hydrochloride salt.
160 to 170 °C (320 to 338 °F; 433 to 443 K) Boiling point for freebase at 0.05mm/Hg.
2.75270
7.42x10−07mm/Hg
Refractive index (nD)
1.614
Pharmacology
Oral, Vaporized
Unknown, likely under several hours.
Several hours.
Hazards
200.3 °C (392.5 °F; 473.4 K)
Lethal dose or concentration (LD, LC):
LDLo (lowest published)
6250 μg/kg (Rat)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
5-MeO-pyr-T (5-methoxy-N,N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It is the 5-methoxy analogofpyr-T. 5-MeO-pyr-T was first synthesized by Hunt & Brimblecombe,[1] who credited S. Mitzal for characterization of chemical properties.[2] Later human tests were reported by Alexander Shulgin, in his book TiHKAL. An oral dosage of 0.5 to 2 mg, and an inhaled dosage of 2–3 mg are reported. 5-MeO-pyr-T causes varying reactions, such as amnesia, tinnitus, vomiting, and a 5-MeO-DMT-like rushing sensation. At the highest dosage reported in TiHKAL, the subject describes awakening from an apparent fugue state during which they were wandering the streets, with complete amnesia upon awakening.[3]
Testing was performed on rats using this compound while characterizing various agonists of the 5-HT7 receptor. It is an agonist with a Ki value of 630.96nM.[4]
Very little other data exists about the pharmacological properties, metabolism, and toxicity of 5-MeO-pyr-T.
